title: Morbidity of the abdominal wall resection and reconstruction after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
abstract: BACKGROUND
  CRS/HIPEC has evolved as a therapeutic option for selected patients with peritoneal surface malignancies. To achieve complete cytoreduction (CC), some patients require extensive abdominal-wall resection (AWR) and subsequent complex reconstructions, which may be associated with wound complications (WC) and delay of postoperative cancer therapy.
  
  
  METHODS
  Review of a prospective database of 350 patients revealed 213 patients with peritoneal carcinomatosis who underwent AWR due to suspected or proven wound/port site metastases during CRS/HIPEC. Tumor origin included: appendix, colon, ovarian, peritoneal mesothelioma, primary peritoneal, and others. WC were related to peritoneal carcinomatosis index (PCI), CC score, length of surgery, type of AWR and closure, blood transfusion, and albumin levels using binary logistic regression (odds ratios (OR) and 95 % CIs) analysis.
  
  
  RESULTS
  PCI ≥ 20 was found in 151 (71 %), CC was achieved in 178 (84 %). Mean length of surgery was 613 min. Postoperative WC were detected in 49 of 213 (23 %) patients, 13 (6 %) had Grade III (according to Clavien-Dindo's classification) WC, and led to delay of postoperative chemotherapy. WC occurred in 21 of 64 (32.8 %) patients with excision of port sites (odds ratio [OR] = 2.11, confidence interval [CI] = 1.09-4.10, p = 0.026). Primary fascial closure was performed in 191 of 213 (89.7 %) patients, 40 (21 %) of whom had WC. Mesh-assisted abdominal wall reconstruction was required in 22 of 213 (10.3 %) patients, of whom 9 (40.9 %) had WC (OR = 2.61, CI = 1.04-6.55, p = 0.035).
  
  
  CONCLUSIONS
  Port-site excision and mesh-assisted abdominal wall reconstruction were associated with higher incidence of postoperative WC following CRS/HIPEC. The implications of these preliminary findings may need to be considered during surgical planning for these patients.
authors.affiliation: Institute for Cancer Care at Mercy Medical Center, Baltimore, MD, USA.
authors.forename: Maria F
authors.initials: MF
authors.lastname: Nunez
authors.forename: Armando
authors.initials: A
authors.lastname: Sardi
authors.forename: Carol
authors.initials: C
authors.lastname: Nieroda
authors.forename: William
authors.initials: W
authors.lastname: Jimenez
authors.forename: Michelle
authors.initials: M
authors.lastname: Sittig
authors.forename: Ryan
authors.initials: R
authors.lastname: MacDonald
authors.forename: Nail
authors.initials: N
authors.lastname: Aydin
authors.forename: Vladimir
authors.initials: V
authors.lastname: Milovanov
authors.forename: Vadim
authors.initials: V
authors.lastname: Gushchin
mesh_terms: D034861:Abdominal Wall / Q000473:pathology / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D009367:Neoplasm Staging; D009369:Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy; D010534:Peritoneal Neoplasms / Q000150:complications / Q000556:secondary / Q000628:therapy; D011183:Postoperative Complications; D011379:Prognosis; D011446:Prospective Studies; D019651:Plastic Surgery Procedures; D014946:Wound Infection / Q000209:etiology*